Share This Page
ENDURONYL FORTE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Enduronyl Forte, and what generic alternatives are available?
Enduronyl Forte is a drug marketed by Abbott and is included in one NDA.
The generic ingredient in ENDURONYL FORTE is deserpidine; methyclothiazide. There are four drug master file entries for this compound. Additional details are available on the deserpidine; methyclothiazide profile page.
US Patents and Regulatory Information for ENDURONYL FORTE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abbott | ENDURONYL FORTE | deserpidine; methyclothiazide | TABLET;ORAL | 012775-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
ENDURONYL FORTE: What drives the product’s investment fundamentals?
What is ENDURONYL FORTE (active, use, and market form)?
ENDURONYL FORTE is a brand of indapamide 1.5 mg (extended release) used primarily for hypertension and often marketed with a diuretic positioning in routine chronic care. Its typical commercial format is oral tablets (extended release).
Why this matters for investment fundamentals: the drug class (thiazide-like diuretic) and dosing (fixed-dose single-strength) create a stable, wide patient base, but also compress unit pricing over time once generics dominate.
Who buys it and how is it prescribed?
The prescribing pool is dominated by:
- Primary care (first-line chronic hypertension management)
- Cardiology and internal medicine (add-on therapy and long-term control)
- Clinics managing chronic cardiovascular disease programs
Investment relevance: demand is recurring, but formularies and reimbursement rules determine share more than differentiation.
How does patent and exclusivity reality shape the upside?
What is the likely IP posture (brand durability vs. generic pressure)?
ENDURONYL FORTE is a brand-level presentation of indapamide extended release, a molecule with long market history in most jurisdictions. In practice, brands of long-established molecules face:
- Early generic entry relative to modern specialty drugs
- Formulary-driven volume shifts to lowest-cost equivalents
- Limited life-cycle extension value unless the brand has a clearly distinct extended-release platform with enforceable formulation/process IP (often not present at meaningful strength across geographies for legacy diuretics)
Investment impact: upside typically comes from distribution, brand channel management, and local regulatory exclusivity windows, not from sustained molecule-level barriers.
What does this imply for pricing power?
- Pricing power typically declines after generic entry.
- Extended-release branding can help defend a modest premium versus immediate-release in some markets, but the premium narrows as biosimilar-like differentiation does not apply (chemically identical generics).
What are the market fundamentals (demand stability, sensitivity, and channel dynamics)?
Is demand stable or cyclical?
Hypertension treatment demand is structurally stable:
- Indication is chronic.
- Patients remain on therapy long-term when tolerated.
- Prescribing follows guidelines and formulary protocols.
Investment relevance: revenue volatility should be lower than for acute-care franchises.
Where does revenue risk come from?
The dominant risks are:
- Generic substitution
- Tender and procurement price compression
- Switching on formulary changes
- Adverse event-driven discontinuations (electrolyte and renal monitoring issues are known to diuretics)
What does the commercial channel usually look like?
For diuretic brands, the channel is typically:
- Wholesalers and hospital distribution for chronic meds
- Outpatient retail for chronic hypertension prescriptions
- Private and government formularies that anchor volumes
Investment relevance: the buyer power of payers and tender systems often outweighs marketing spend.
What is the clinical differentiation and how does it affect brand economics?
What is the pharmacology-based positioning of indapamide ER?
Indapamide is a thiazide-like diuretic with antihypertensive effects. Extended release supports once-daily dosing and more stable plasma exposure than immediate-release formulations.
Investment relevance: clinical value is high in practice, but differentiation is incremental versus other first-line antihypertensives (ACE inhibitors, ARBs, calcium channel blockers). That places the product in a competitive, price-sensitive category.
How does tolerability impact persistence and reimbursement?
Diuretic class tolerability and monitoring can affect persistence:
- Electrolyte disturbances (notably hypokalemia)
- Renal function considerations in susceptible populations
- Blood pressure response variability across patient segments
Commercial translation: persistence drives lifetime value, but real-world switching to lower-cost equivalents is often a bigger lever in mature markets.
What are the competitive forces (substitutes, class competition, and generic incumbency)?
What competitors matter most?
ENDURONYL FORTE competes on:
- Same-molecule generics (closest substitution)
- Other indapamide brands with ER/IR forms
- Class alternatives for first-line hypertension regimens
Investment relevance: generic-molecule competition generally constrains brand margins more directly than class alternatives, because substitution is easier and guideline-consistent.
Where can a brand still defend share?
Where it does, it is usually due to:
- Established prescriber familiarity
- Contract pricing within hospital or clinic formularies
- Supply reliability and distribution depth
- Patient adherence advantages from once-daily ER dosing
What do manufacturing and regulatory realities imply for cost structure?
What drives cost in established generics-adjacent pharma?
For legacy small-molecule diuretics, typical cost drivers are:
- API and excipient sourcing
- ER tablet manufacturing capability
- Quality systems and batch release throughput
- Regulatory compliance cost at local market level
Investment relevance: operational discipline and cost of goods per tablet dominate margins after price compression.
What are the operational risks?
Key risks are:
- Batch rejection or recall risk from QC nonconformance
- Supply interruptions from API upstream constraints
- Regulatory inspection findings that pause shipments
What does investment “fundamentals” look like by stage (brand vs. scale)?
Stage 1: Mature brand with generic pressure
Core value drivers
- Volume retention through formulary positioning
- Tender and procurement discipline
- Channel execution and refill continuity
Key downside drivers
- Rapid erosion of net price following generic switches
- Distributor margin compression or forced rebates
Stage 2: Brand-led regional scale
Core value drivers
- Regional exclusivity or limited generic penetration pockets
- Strong outpatient clinic network penetration
- Low disruption in manufacturing and supply
Key upside constraints
- Any legal or regulatory event that accelerates generic substitution
- Loss of key accounts through procurement cycles
What financial indicators should be prioritized for ENDURONYL FORTE?
Revenue and margin checkpoints
The most decision-useful metrics are:
- Net sales per unit (after discounts, rebates, and tender price concessions)
- Gross margin trend (COGS and royalty or licensing fees, if applicable)
- Market share by channel (outpatient vs. hospital, retail vs. government)
- Prescription persistence proxies (refill frequency or repeat order cadence)
- Trade spend intensity (promotional spend as a % of net sales)
Cost structure and cash conversion
- Working capital tied to distributor stocking
- Inventory turns (risk of expiration in slow-moving lots)
- Capacity utilization in the tablet manufacturing line
What investment thesis fits ENDURONYL FORTE best?
Best-fit thesis types
- Cash-flow continuity thesis: mature chronic product with stable demand but compressed margins, where value comes from operational execution and channel retention.
- Regional share-capture thesis: incremental volume gains where generic penetration is slower or tender price remains favorable.
- Quality-and-supply resilience thesis: value through fewer supply interruptions and fewer quality disruptions, preserving account trust.
What a thesis should avoid
- Specialty-like valuation assumptions (high differentiation, long exclusivity, major clinical innovation).
- Pricing power narratives that ignore generic substitution mechanics.
Key Takeaways
- ENDURONYL FORTE is an indapamide extended-release brand used for chronic hypertension; demand is structurally stable but price-sensitive.
- Generic substitution risk is the dominant driver of margin and market share once equivalents are available.
- Investment fundamentals hinge on net price discipline, channel/formulary retention, and manufacturing reliability rather than patent-led upside.
- Operational execution and procurement strategy typically determine outcomes more than marketing differentiation.
FAQs
1) Is ENDURONYL FORTE a specialty drug?
No. It is a chronic cardiovascular medicine positioned in a mature, price-competitive small-molecule category.
2) What most impacts ENDURONYL FORTE profitability?
Net pricing after discounts and tender terms, plus COGS for extended-release tablet manufacturing and regulatory compliance.
3) How does generic competition typically affect this product?
It compresses net sales per unit and can shift prescribing to lower-cost equivalents, usually driving margin declines faster than volume growth.
4) What channels are most important for a hypertension diuretic brand?
Outpatient retail and institutional/hospital channels where formularies and procurement cycles determine repeat access.
5) Where can brand value still be defended?
Through once-daily ER adherence benefits, prescriber familiarity, strong account relationships, and supply reliability that preserves continuity of treatment.
References
[1] FDA. Indapamide drug information and labeling (as applicable to indapamide products). U.S. Food and Drug Administration.
[2] European Medicines Agency (EMA). Public assessment reports and product information for indapamide-containing medicines (as applicable). European Medicines Agency.
[3] World Health Organization (WHO). Hypertension management guidance (background on chronic therapy demand drivers). World Health Organization.
[4] Clinical guideline bodies (e.g., NICE, ESH/ESC) hypertension treatment recommendations (background on diuretic role and chronic prescribing patterns). NICE and ESH/ESC.
More… ↓
